【Clin Breast Cancer】乳腺癌柔脑膜转移患者采用系统治疗可延长存活期
作者认为，只有系统治疗会延长乳腺癌柔脑膜转移患者的生存期。放射治疗和鞘内疗法虽然可改善患者症状和体征，但对存活期无益。
该项前瞻性观察研究共纳入149例乳腺癌柔脑膜转移的女性患者。作者分别评估了系统治疗和局部疗法对患者的疗效，发现采用不同的治疗方案，只有系统治疗可延长患者存活期。局部疗法，无论是放射治疗还是药物化疗(鞘内注射甲氨蝶呤或阿糖胞苷脂质体)仅可提升生活质量，但不能延长存活期。
作者认为，只有系统治疗会延长乳腺癌柔脑膜转移患者的生存期。放射治疗和鞘内疗法虽然可改善患者症状和体征，但对存活期无益。
TAKE-HOME MESSAGE
This is a prospective observational study of 149 women with metastatic breast cancer with leptomeningeal involvement. The authors evaluated systemic therapy versus local therapy in the management of these patients. They found that, among the different treatment options, systemic therapy was the only option to prolong survival. Local therapy either with radiation or chemotherapy (intrathecal methotrexate or liposomal cytarabine) improved quality of life but not survival.
The authors conclude that only systemic therapy resulted in prolonged survival in patients with leptomeningeal metastasis. While both radiation therapy and lumbar intrathecal therapy improved signs and symptoms, survival did not improve.
Clinical Breast Cancer
Breast Cancer Leptomeningeal Metastasis: The Results of Combined Treatment and the Comparison of Methotrexate and Liposomal Cytarabine as Intra-CSF Chemotherapy
相关文章
评论
我要跟帖
.jpg)
